Deaths in the era of HAART: Contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers

AIDS

Volumn 20, Issue 1, 2006, Pages 67-71

  Sabin, Caroline A ^a   Smith, Colette J ^a   Youle, Mike ^b   Lampe, Fiona C ^a   Bell, Di Robertson ^b   Puradiredja, Dewi ^a   Lipman, Marc C I ^b   Bhagani, Sanjay ^b   Phillips, Andrew N ^a   Johnson, Margaret A ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Abnormal laboratory measurements; Cause of death; Genotypic resistance; HAART; Mortality

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; CELL COUNT; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; VIRUS RESISTANCE;

EID: 29144446133     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000196178.73174.24     Document Type: Review

References (15)

1. Sullivan AK, Curtis H, Sabin CA, Johnson MA. National Review of newly diagnosed HIV infections. Br Med J 2005; 330:1301-1302.
2. Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, Phillips AN, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004; 18:2145-2151.
3. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
4. Hicks C, Currier J, Sax P, Sherer R, Wanke C. Current management challenges in HIV: tolerability of antiretrovirals and metabolic complications. AIDS Patient Care STD 2003; 17:221-233.
5. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego G, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17:1467-1471.
6. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005; 19:1081-1089.
7. Sabin CA, Lampe FE, Chaloner C, Madge SJ, Lipman MCI, Youle M, et al. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use. AIDS 2003; 4:87-93.
8. International AIDS Society-USA. HIV Drug Resistance Mutations. San Francisco, CA: International AIDS Society-USA; 2005. http://www.iasusa.org/ resistance_mutations/index.html.
9. The UK Collaborative Group on HIV Drug Resistance. Estimating HIV-1 drug resistance in antiretroviral treated individuals within the UK. J Infect Dis 2005; 192:967-973.
10. Recsky MA, Brumme ZL, Chan KJ, Wynhoven B, Yip B, Dong WWY, et al. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis 2004; 190: 285-292.
11. Lucas CM, Gallant JE, Moore RD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS 2004; 18:1539-1548.
12. Lundgren JD, Mocroft A. Anaemia and survival in human immunodeficiency virus. Clin Infect Dis 2003; 37 (Suppl 4): S297-S303.
13. Feldman JG, Gange SJ, Bacchetti P, Cohen M, Young M, Squires KE, et al. Serum albumin is a powerful predictor of survival among HIV-1 infected women. J Acquir Immune Defic Syndr 2003; 33:66-73.
14. Weber R, Friis-Moller N, Sabin CA, Reiss P, D'Arminio Monforte A, Dabis F, et al. HIV and non-HIV-related deaths and their relationship to immunodeficiency: The DAD Study. Twelfth Conference on Retroviruses and Opportunistic Infections. Boston, February 2005 [abstract 595].
15. CHIP. The CoDe [Coding of Death in HIV] Project. Copenhagen: Copenhagen HIV Programme. http://www.cphiv.dk/default.asp? submenu_id=329&topimg=29.